Journals / Çukurova Anestezi ve Cerrahi Bilimler Dergisi / 2021 / Cilt: 4 - Sayı: 1

Pediatric Brainstem Glioblastoma: A Systematic Review about Treatment Strategies

Lynch sendromunda profilaktik cerrahi: Ne zaman ve nasıl?– Güncel yaklaşımlar ve literatür derlemesi

Pages
37–44
Publication Date
2021-04-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to literature, the median overall survival of these patients are approximately between 9 to 12 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Brainstem tumors are rare pathologies, brainstem glioblastoma is even rarer.
📊
Key Findings & Data:According to literature, the median overall survival of these patients are approximately between 9 to 12 months.
💡
Conclusion & Impact:Radiotherapy is associated with a decreased risk of mortality at 9 months but not long-term.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:LYNCH sendromu · Herediter polipozis sendromu · Profilaktik cerrahi

Abstract

Brainstem tumors are rare pathologies, brainstem glioblastoma is even rarer. We report three pediatric patients who underwent subtotal tumor resection for brainstem tumors diagnosed as brainstem glioblastoma. The clinical courses and treatment procedures were discussed alongside a comprehensive literature review. Treatment of brainstem high-grade gliomas includes steroids, surgery, radiotherapy, and chemotherapy. However, none of these treatment modalities effectively prolongs survival time. According to literature, the median overall survival of these patients are approximately between 9 to 12 months. Glioblastoma has a poor prognosis in pediatric patients with high-grade brainstem gliomas. Radiotherapy is associated with a decreased risk of mortality at 9 months but not long-term.

Özet

Lynch sendromu; kolorektal kansere dönüşen soliter adenomlar ve ekstra-kolonik manifestasyonlarla karakterize, otozomal dominant kalıtımlı bir kanser predispozan sendromdur. Sendromun tanısı klinik bulgular, patolojik özellikler, aile öyküsü ve genetik testler ile koyulabilir. Lynch Sendromu riski altında olan bireylerde tarama çalışmalarına 20’ li yaşlardan itibaren başlanmalı, mutasyon pozitif taşıyıcılarında yıllık olarak devam edilmeli ve belli şartların varlığında da da profilaktik cerrahi gündeme alınmalıdır.

🔖

Cite This Article

AKIN, E., DÜLGER, U. C., ALTINTOPRAK, F. (2021). Pediatric Brainstem Glioblastoma: A Systematic Review about Treatment Strategies. Çukurova Anestezi ve Cerrahi Bilimler Dergisi, Cilt: 4 - Sayı: 1, 37–44. https://ajindex.com/articles/483849

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Boland CR, Lynch HT. The history of Lynch syndrome. Fam Cancer. 2013;12(2):145-57. Doi: 10.1007/s10689-013-9637-8
  2. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66(3):589–600. doi: 10.1016/0092-8674(81)90021-0
  3. Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015;15(3):181-94. doi: 10.1038/nrc3878
  4. Jass J, Stewart S, Stewart J, Lane MR. Hereditary non-polyposis colorectal cancer--morphologies, genes and mutations. Mutat Res. 1994;310(1):125–33. doi: 10.1016/0027-5107(94)90016-7
  5. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919-32. doi: 10.1056/NEJMra012242
  6. Win AK, Young JP, Lindor NM, Tucker MK, Ahnen DJ, Young GP,et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012;30(9):958-64. doi: 10.1200/JCO.2011.39.5590
  7. Guillem JG, Smith AJ, Calle JP, Ruo L. Gastrointestinal polyposis syndromes. Curr Probl Surg. 1999;36(4):217-323. doi: 10.1016/s0011-3840(99)80013-6
  8. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, et al. PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016;18(1):13-9. doi: 10.1038/gim.2015.27 9. de Rosa N, Rodriguez-Bigas MA, Chang GJ, Veerapong J, Borras E, Krishnan S,et al. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol. 2016;34(25):3039-46
  9. Kastrinos F, Stoffel EM. History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol 2014;12(5):715-27; quiz e41-3
  10. Brixen LM, Bernstein IT, Bulow S, Ehrnrooth E. Survival of patients with Stage III colon cancer is improved in hereditary non-polyposis colorectal cancer compared with sporadic cases. A Danish registry based study. Colorectal Dis. 2013;15(7):816-23
  11. Yang Y, Nancy YY. Comprehensive clinical genetics care for patients with inherited colorectal cancer associated with Lynch syndrome: Western and Asian perspectives. Chin Clin Oncol. 2018;7(1):9. doi: 10.21037/cco.2018.01.06 13. Fitzgibbons RJ Jr, Lynch HT, Stanislav GV, Watson PA, Lanspa SJ, Marcus JN, et al. Recognition and treatment of patients with he- reditary no